Gosset Ownership
Private
Therapeutic Areas
Stage
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Adiso Therapeutics General Information
Adiso has multiple clinical programs including ADS051 in Phase 2 for ulcerative colitis, ADS032 in IND enabling stage for respiratory and dermal conditions, and ADS024 in preclinical development for neuroinflammation. The company has completed enrollment in the third cohort of its Phase 1b study of ADS051 for moderate-to-severe ulcerative colitis.
Contact Information
Website
Primary Industry
Biotech
Corporate Office
Concord, Massachusetts
United States
United States
Drug Pipeline
ADS051
Phase 1Key Partnerships
Adiso Therapeutics Funding
No funding data available
To view Adiso Therapeutics's complete valuation and funding history, request access »